PTX Media related, page-445

Definitely not a bad thing for PTX Shell.

As you said the OmniCar platform is cell agnostic.

Any cell, including the one identified in the article can be used in conjunction with the OmniCar platform.

Consider the different cells the warhead & OmniCar the ballistic missile with laser guidance...Turning a rudimentary cell therapy into a highly targeted and critical controllable therapy that enables bunker busting of solid tumours...It's a beautiful modular system, completely cell interchangeable that can adapt to any mutations and or attack multiple cancer profiles simultaneously as needed.

If the in vitro tests are any indication...Phase 1 trials could see some fireworks for the medical community and shareholders...Definitely worth keeping in the portfolio from my perspective.

Cheers.